The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10913 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin-resistant

NOT Open Access | Novel molecule combinations and corresponding hybrids targeting artemisinin-resistant Plasmodium falciparum parasites

May 5, 2021 - 11:03 -- NOT Open Access
Author(s): 
Ouji M, Nguyen M, Mustière R, Jimenez T, Augereau JM, Benoit-Vical F, Deraeve C
Reference: 
Bioorg Med Chem Lett. 2021 May 1;39:127884

Malaria is still considered as the major parasitic disease and the development of artemisinin resistance does not improve this alarming situation. Based on the recent identification of relevant malaria targets in the artemisinin resistance context, novel drug combinations were evaluated against artemisinin-sensitive and artemisinin-resistant Plasmodium falciparum parasites.

Diversity-oriented synthesis derived indole based spiro and fused small molecules kills artemisinin-resistant Plasmodium falciparum

February 20, 2021 - 08:37 -- Open Access
Author(s): 
Akshaykumar Nayak, Himani Saxena, Chandramohan Bathula, Tarkeshwar Kumar, Souvik Bhattacharjee, Subhabrata Sen and Ashish Gupta
Reference: 
Malaria Journal 2021 20:100, 17 February 2021

Despite numerous efforts to eradicate the disease, malaria continues to remain one of the most dangerous infectious diseases plaguing the world. In the absence of any effective vaccines and with emerging drug resistance in the parasite against the majority of anti-malarial drugs, the search for new drugs is urgently needed for effective malaria treatment.

Orthosteric-allosteric dual inhibitors of PfHT1 as selective antimalarial agents

January 20, 2021 - 07:40 -- Open Access
Author(s): 
Huang J, Yuan Y, Yin H, et al.
Reference: 
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2017749118

Artemisinin-resistant malaria parasites have emerged and have been spreading, posing a significant public health challenge. Antimalarial drugs with novel mechanisms of action are therefore urgently needed. In this report, we exploit a "selective starvation" strategy by inhibiting Plasmodium falciparum hexose transporter 1 (PfHT1), the sole hexose transporter in P. falciparum, over human glucose transporter 1 (hGLUT1), providing an alternative approach to fight against multidrug-resistant malaria parasites. The crystal structure of hGLUT3, which shares 80% sequence similarity with hGLUT1, was resolved in complex with C3361, a moderate PfHT1-specific inhibitor, at 2.3-Å resolution.

Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea

December 16, 2020 - 09:38 -- Open Access
Author(s): 
Miotto O, Sekihara M, Mita T, et al.
Reference: 
PLoS Pathog. 2020 Dec 15;16(12):e1009133

The rapid and aggressive spread of artemisinin-resistant Plasmodium falciparum carrying the C580Y mutation in the kelch13 gene is a growing threat to malaria elimination in Southeast Asia, but there is no evidence of their spread to other regions. We conducted cross-sectional surveys in 2016 and 2017 at two clinics in Wewak, Papua New Guinea (PNG) where we identified three infections caused by C580Y mutants among 239 genotyped clinical samples. One of these mutants exhibited the highest survival rate (6.8%) among all parasites surveyed in ring-stage survival assays (RSA) for artemisinin.

No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China–Myanmar border

September 15, 2020 - 10:38 -- Open Access
Author(s): 
Fang Huang, Biraj Shrestha, Hui Liu, Lin-Hua Tang, Shui-Sen Zhou, Xiao-Nong Zhou, Shannon Takala-Harrison, Pascal Ringwald, Myaing M. Nyunt and Christopher V. Plowe
Reference: 
Malaria Journal 2020 19:334, 14 September 2020

The emergence and spread of artemisinin resistance in Plasmodium falciparum poses a threat to malaria eradication, including China’s plan to eliminate malaria by 2020. Piperaquine (PPQ) resistance has emerged in Cambodia, compromising an important partner drug that is widely used in China in the form of dihydroartemisinin (DHA)-PPQ. Several mutations in a P. falciparum gene encoding a kelch protein on chromosome 13 (k13) are associated with artemisinin resistance and have arisen spread in the Great Mekong subregion, including the China–Myanmar border. Multiple copies of the plasmepsin II/III (pm2/3) genes, located on chromosome 14, have been shown to be associated with PPQ resistance.

NOT Open Access | Half-Sandwich Cyclopentadienylruthenium(II) Complexes: A New Antimalarial Chemotype

August 25, 2020 - 15:34 -- NOT Open Access
Author(s): 
Milheiro SA, Gonçalves J, Moreira R, et al.
Reference: 
Inorg Chem. 2020 Aug 24

A small library of "half-sandwich" cyclopentadienylruthenium(II) compounds of the general formula [(η5-C5R5)Ru(PPh3)(N-N)][PF6], a scaffold hitherto absent from the toolbox of antiplasmodials, was screened for activity against the blood stage of CQ-sensitive 3D7-GFP, CQ-resistant Dd2, and artemisinin-resistant IPC5202 Plasmodium falciparum strains and the liver stage of Plasmodium berghei.

Molecular characterization of Plasmodium falciparum DNA-3-methyladenine glycosylase

August 10, 2020 - 15:00 -- Open Access
Author(s): 
Nattapon Pinthong, Paviga Limudomporn, Jitlada Vasuvat, Poom Adisakwattana, Pongruj Rattaprasert and Porntip Chavalitshewinkoon-Petmitr
Reference: 
Malaria Journal 2020 19:284, 6 August 2020

The emergence of artemisinin-resistant malaria parasites highlights the need for novel drugs and their targets. Alkylation of purine bases can hinder DNA replication and if unresolved would eventually result in cell death. DNA-3-methyladenine glycosylase (MAG) is responsible for the repair of those alkylated bases. Plasmodium falciparum (Pf) MAG was characterized for its potential for development as an anti-malarial candidate.

NOT Open Access | Identification of compounds active against quiescent artemisinin-resistant Plasmodium falciparum parasites via the quiescent-stage survival assay (QSA)

July 14, 2020 - 15:42 -- NOT Open Access
Author(s): 
Reyser T, Paloque L, Ouji M, Nguyen M, Ménard S, Witkowski B, Augereau JM, Benoit-Vical F
Reference: 
J Antimicrob Chemother. 2020 Jul 12:dkaa250

Quiescence is an unconventional mechanism of Plasmodium survival, mediating artemisinin resistance. This phenomenon increases the risk of clinical failures following artemisinin-based combination therapies (ACTs) by slowing parasite clearance and allowing the selection of parasites resistant to partner drugs.

Not Open Access | Pyronaridine-artesunate Efficacy and Safety in Uncomplicated Plasmodium falciparum Malaria in Areas of Artemisinin-resistant Falciparum in Viet Nam (2017-2018)

May 13, 2020 - 06:42 -- NOT Open Access
Author(s): 
Quang Bui P, Hong Huynh Q, Thi Ta T, et al.
Reference: 
Clinical Infectious Diseases, Volume 70, Issue 10, 15 May 2020, Pages 2187–2195

Multidrug-resistant Plasmodium falciparum undermines the efficacy of currently deployed antimalarial therapies in southern Viet Nam.

NOT Open Access | Pyronaridine-artesunate Shows Promise as an Effective and Well-tolerated Treatment for Artemisinin-resistant Plasmodium falciparum Malaria

May 12, 2020 - 17:51 -- NOT Open Access
Author(s): 
Okombo J, Fidock DA
Reference: 
Clin Infect Dis. 2020 May 6;70(10):2196-2198

Artemisinin-based combination therapies (ACTs) are the recommended first-line antimalarials for uncomplicated malaria and comprise a short-acting artemisinin-based component for rapid reduction of Plasmodium parasite burden partnered with a longer-acting drug to eliminate surviving parasites.

Pages

Subscribe to RSS - artemisinin-resistant